Evidence map›Paper›PMID 39564144›Full record

ArticleClinical hematology international2024

Nurses' reported training needs for advanced cell therapies: a survey on behalf of the Nurses Group of the EBMT.

Michelle Kenyon, Sarah Jayne Liptrott, Annika Kisch, Jarl Mooyaart, Brian Piepenbroek, Daphna Hutt, Isabel Salcedo, Annalisa Ruggeri, Cristian Chabannon, Rose Ellard and 1 more

Abstract read
In one paragraph

Article in Clinical hematology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Michelle KenyonDepartment of Haematological Medicine, 4th Floor Hambledon Wing West, King's College Hospital NHS Foundation Trust, Denmark Hill, London, United Kingdom.
Sarah Jayne LiptrottNursing Development and Research Unit, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), via Gallino 12, 6500, Bellinzona, Switzerland.
Annika KischDepartment of Hematology, Oncology and Radiation Physics, Skane University Hospital, Lund, Sweden.
Jarl MooyaartEBMT Leiden Statistical Unit, Rijnsburgerweg 10, 2333 AA, Leiden, The Netherlands.
Brian PiepenbroekEBMT Leiden Study Unit, Rijnsburgerweg 10, 2333 AA, Leiden, The Netherlands.
Daphna HuttDepartment of Paediatric Hematology-Oncology and BMT, Edmond and lily Safra Children Hospital, Sheba Medical center, Ramat-Gan 5265601 Israel.
Isabel SalcedoHospital Universitario Puerta de Hierro Majadahonda, Spain; Instituto de Investigación Sanitaria Puerta de Hierro-Segovia Arana. Calle Joaquín Rodrigo 2, 28222 Majadahonda, Spain.
Annalisa RuggeriDept of Hematology, IRCCS San Raffaele Scientific Institute, 20135 Milano, Italy.
Cristian ChabannonCentre de Thérapie Cellulaire. Institut Paoli-Calmettes Comprehensive Cancer Centre & module Biothérapies du Centre d'Investigations Cliniques de Marseille, Inserm CBT-1409, Aix-Marseille Université, AP-HM, Institut Paoli-Calmettes. Marseille, France.
Rose EllardThe Royal Marsden NHS Foundation Trust, London, UK.
John MurrayHaematology and Transplant Unit The Christie NHS FT, Manchester, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Advanced Therapy Medicinal Products (ATMPs) for human use have advanced globally with the rapid adoption of Chimeric Antigen Receptor T-cell (CAR-T) therapies in haemato-oncology. CAR-T cell therapy and ATMPs have unique, significant acute and chronic toxicities, and appropriate patient care is crucial. Significant challenges, including the need for nurse education and training, accompany optimal patient success and benefits. Objectives: This study aimed to describe nurses' training needs in relation to ATMP management and patient care. Methods: A cross-sectional online survey was performed by the European Society for Blood and Marrow Transplantation, based on a previously tested questionnaire developed in the UK. Findings: 109 complete responses from 86 different centers from 24 countries were returned (1207 distributed). Over 1/3 reported experience delivering licensed ATMPs (CAR-T). High-priority training areas included a general introduction to ATMPs, toxicity management, product-specific information, and regulatory frameworks for ATMPs. A clear need for ATMP-specific training exists and is regarded as important. Training prior to implementation is key and should be supported by ongoing competency maintenance. Counseling, patient support, and long-term follow-up are identified for future training and opportunities for nurse experience sharing in this rapidly evolving field.

Indexed as

ATMPCAR-Tcellular therapyeducationgene therapynursing care

Identifiers

PMID39564144
PMCPMC11574697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.